hepatitis C

JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
Drug Channels
JAMA
drug pricing
340B
hepatitis C
Flag link:
CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs
CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs
Biopharma Dive
hepatitis C
Medicaid
Netflix model
Louisiana
Gilead Sciences
CMS
Flag link:
June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more
June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more
BioCentury
Washington
Netflix model
hepatitis C
BGI Genomics
China
distribution
Flag link:
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
Biopharma Dive
AbbVie
hepatitis C
Netflix model
Washington state
Flag link:
Louisiana has picked its 'Netflix' hepatitis C partner: Gilead's new generics unit
Louisiana has picked its 'Netflix' hepatitis C partner: Gilead's new generics unit
Fierce Pharma
Louisiana
Gilead Sciences
hepatitis C
Asegua Therapeutics
Netflix model
Flag link:
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck
Fierce Pharma
hepatitis C
AbbVie
Gilead Sciences
Louisiana
Netflix model
Flag link:
Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections
Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections
Stat
Purdue Pharma
oxycontin
abuse-resistant painkillers
hepatitis C
Flag link:
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Fierce Pharma
Gilead Sciences
hepatitis C
Epclusa
drug ads
television ads
Flag link:
7 Things to Expect for Gilead Sciences in 2019
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Gilead Sciences
JPMHC 2019
HIV
hepatitis C
M&A
Daniel O'Day
Flag link:
Did Gilead Sciences Make an $11 Billion Blunder?
Did Gilead Sciences Make an $11 Billion Blunder?
Motley Fool
Gilead Sciences
Pharmasset
hepatitis C
Flag link:
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
Fierce Pharma
AbbVie
hepatitis C
Mavyret
Medicines Patent Pool
Flag link:
Merck asks SCOTUS for its $200M in Gilead patent dues, never mind the misconduct
Merck asks SCOTUS for its $200M in Gilead patent dues, never mind the misconduct
Fierce Pharma
Merck
Supreme Court
Gilead Sciences
hepatitis C
Flag link:
Express Scripts praises, then takes credit for Gilead's authorized generics launches
Express Scripts praises, then takes credit for Gilead's authorized generics launches
Fierce Pharma
Gilead Sciences
Express Scripts
generics
hepatitis C
Flag link:
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
CP Wire
Gilead Sciences
generics
Epclusa
Harvoni
hepatitis C
Asegua Therapeutics
Flag link:
Inovio launches Ph1 study of Hep C vaccine
Inovio launches Ph1 study of Hep C vaccine
Drug Delivery Business News
Inovio
vaccines
GeneOne Life Science
hepatitis C
GLS-6150
Flag link:
Louisiana seeking comments on 'Netflix' model for hepatitis C drugs
Louisiana seeking comments on 'Netflix' model for hepatitis C drugs
Fierce Pharma
hepatitis C
Medicaid
Louisiana
Flag link:
2019 Express Scripts Formulary Exclusions: Hepatitis C Changes Show Why the Drug Channel Must Change, Too
2019 Express Scripts Formulary Exclusions: Hepatitis C Changes Show Why the Drug Channel Must Change, Too
Drug Channels
Express Scripts
CVS Health
formulary
drug channels
hepatitis C
Flag link:
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
Endpoints
China
Gilead Sciences
hepatitis C
generics
Sovaldi
Flag link:
Merck’s 60% price cut for hepatitis C drug nets company a big sales opportunity
Merck’s 60% price cut for hepatitis C drug nets company a big sales opportunity
Marketwatch
Merck
Express Scripts
hepatitis C
Zepatier
Flag link:
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Bloomberg
Express Scripts
PBMs
Gilead Sciences
HIV
Atripla
AbbVie
Mavyret
hepatitis C
Flag link:

Pages